Related Experiment Video

Updated: May 9, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Hormones and arterial stiffness in patients with chronic kidney disease

Ozkan Gungor1, Fatih Kircelli, Luminita Voroneanu

  • 1Ege University School of Medicine, Division on Nephrology.

Journal of Atherosclerosis and Thrombosis
|August 6, 2013
PubMed

Insights

Cardiovascular disease is a major cause of death in chronic kidney disease patients. This review examines how hormone changes in chronic kidney disease affect arterial stiffness, a key factor in cardiovascular disease.

Area of Science:

  • Nephrology
  • Cardiology
  • Endocrinology

Background:

  • Cardiovascular disease (CVD) is the leading cause of mortality in patients with chronic kidney disease (CKD).
  • Arterial stiffness is a significant contributor to CVD development and progression.
  • CKD is associated with widespread hormonal alterations, potentially influencing arterial health.

Purpose of the Study:

  • To review existing literature on the relationship between arterial stiffness and hormone levels in CKD patients.
  • To synthesize current knowledge on hormonal factors affecting arterial stiffness in CKD.
  • To compare findings in CKD patients with the general population.

Main Methods:

  • Systematic literature review.
  • Analysis of studies investigating arterial stiffness markers (e.g., pulse wave velocity).
  • Examination of hormonal assays and their correlation with arterial stiffness parameters.

Main Results:

  • Hormonal imbalances common in CKD are linked to increased arterial stiffness.
  • Specific hormones (e.g., parathyroid hormone, fibroblast growth factor 23) show significant associations.
  • Data suggests a distinct pattern of hormonal influence on arterial stiffness in CKD compared to the general population.

Conclusions:

  • Hormonal dysregulation in CKD plays a crucial role in promoting arterial stiffness and CVD.
  • Targeting hormonal pathways may offer novel therapeutic strategies for managing CVD in CKD.
  • Further research is needed to fully elucidate these complex interactions.

More Related Videos

Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy10:35

Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy

Published on: October 19, 2016

Measuring Ascending Aortic Stiffness In Vivo in Mice Using Ultrasound10:08

Measuring Ascending Aortic Stiffness In Vivo in Mice Using Ultrasound

Published on: December 2, 2014

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...